Accueil > Actualité
Actualite financiere : Actualite bourse

Pfizer: positive results for a growth hormone

( - Pfizer and Opko have announced positive results for a Phase III study for Somatrogon, a long-acting human growth hormone to treat children with growth hormone deficiency.

The study showed non-inferiority of this candidate drug in a weekly dose in pre-pubertal children, compared with somatropin in a daily dose, in terms of the growth rate after 12 months of treatment, thus reaching its primary endpoint.

For the record, both groups concluded a somatrogon agreement in 2014, under which Opko is responsible for conducting the clinical program and Pfizer, the drug's registering and marketing.

Copyright (c) 2019 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.